Compare MasterCard Inc (MA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs TransMedics Group Inc — how do they compare? MasterCard Inc trades at $589.14 (market cap $503.50B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: MasterCard Inc is far larger — about 183.8× TransMedics Group Inc's market cap, and MasterCard Inc pays a 0.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and TransMedics Group Inc for 24 Days on average.
| MA | TMDX | |
|---|---|---|
Market Cap | $503.50B | $2.74B |
Volume | 3,390,859 | 949,331 |
Sector | Financials | Health |
52-Week High | $599.86 | $150.42 |
52-Week Low | $471.55 | $61.99 |
Typical Hold Time | 134 Days | 24 Days |
Enterprise Value | $516.53B | $3.13B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $574.76, up 0.82% with strong bullish technical signals. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profit margins above 45%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $666.67 price target.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance. Key risks include payment industry disruption from stablecoins and AI-driven alternatives, though the company's aggressive innovation strategy positions it well. The stock trades at premium valuations (P/E 31.6) but justifies this with consistent earnings growth and market leadership.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
